Vera Therapeutics (VERA) Common Equity (2020 - 2026)
Vera Therapeutics' (VERA) quarterly Common Equity came in at $499.7 million in Q1 2026, down 6.6% YoY from $535.0 million in Q1 2025, and down 17.34% on a QoQ basis from $604.5 million in Q4 2025.
Vera Therapeutics (VERA) Common Equity (2020 - 2026) Analysis & Trends
Vera Therapeutics (VERA) has 7 years of Common Equity data on file, last reported at $499.7 million in Q1 2026.
- Quarterly Common Equity fell 6.6% year-over-year to $499.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $499.7 million (down 6.6% YoY) and the FY2025 annual result came in at $604.5 million, up 4.74% from the prior year.
- Common Equity fell to $499.7 million in Q1 2026, from $604.5 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $604.5 million in Q4 2025 to a low of $76.9 million in Q4 2022.
- A 5-year average of $295.1 million and a median of $289.1 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2024 — Common Equity soared 467.59% — and 2026, when it dropped 6.6%.
- Tracing VERA's Common Equity over 5 years: stood at $76.9 million in 2022, then soared by 32.22% to $101.7 million in 2023, then soared by 467.59% to $577.2 million in 2024, then grew by 4.74% to $604.5 million in 2025, then decreased by 17.34% to $499.7 million in 2026.
- The last three Common Equity figures came in at $499.7 million (Q1 2026), $604.5 million (Q4 2025), and $398.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Vera Therapeutics | 2.28 Bn | 2.28 Bn | - | 407.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 407.76 Mn |
| Mar 31, 2026 | 499.70 Mn |
| Dec 31, 2025 | 604.52 Mn |
| Sep 30, 2025 | 398.88 Mn |
| Jun 30, 2025 | 468.28 Mn |
| Mar 31, 2025 | 535.00 Mn |
| Dec 31, 2024 | 577.16 Mn |
| Sep 30, 2024 | 289.06 Mn |
| Jun 30, 2024 | 327.87 Mn |
| Mar 31, 2024 | 353.54 Mn |
| Dec 31, 2023 | 101.69 Mn |
| Sep 30, 2023 | 123.71 Mn |
| Jun 30, 2023 | 140.52 Mn |
| Mar 31, 2023 | 157.71 Mn |
| Dec 31, 2022 | 76.91 Mn |
| Sep 30, 2022 | 105.72 Mn |
| Jun 30, 2022 | 121.50 Mn |
| Mar 31, 2022 | 134.43 Mn |
| Dec 31, 2021 | 69.59 Mn |
| Sep 30, 2021 | 85.48 Mn |